Eagle Pharmaceuticals (NASDAQ:EGRX) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a research report sent to investors on Thursday. The brokerage issued a hold rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Price Performance

Shares of EGRX stock opened at $0.65 on Thursday. Eagle Pharmaceuticals has a 12 month low of $0.00 and a 12 month high of $6.81. The company’s fifty day simple moving average is $0.68 and its 200-day simple moving average is $2.55.

Institutional Investors Weigh In On Eagle Pharmaceuticals

Several large investors have recently made changes to their positions in the stock. Perceptive Advisors LLC bought a new position in shares of Eagle Pharmaceuticals during the 2nd quarter worth approximately $971,000. RBF Capital LLC lifted its position in Eagle Pharmaceuticals by 11.7% during the third quarter. RBF Capital LLC now owns 143,078 shares of the specialty pharmaceutical company’s stock worth $534,000 after acquiring an additional 14,991 shares during the last quarter. Jacobs Levy Equity Management Inc. acquired a new position in shares of Eagle Pharmaceuticals in the third quarter valued at approximately $453,000. DGS Capital Management LLC grew its position in shares of Eagle Pharmaceuticals by 44.9% in the third quarter. DGS Capital Management LLC now owns 71,728 shares of the specialty pharmaceutical company’s stock valued at $268,000 after purchasing an additional 22,239 shares during the last quarter. Finally, Jane Street Group LLC acquired a new position in Eagle Pharmaceuticals in the 3rd quarter valued at $96,000. Institutional investors and hedge funds own 85.36% of the company’s stock.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.